Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ADAMTS5 | Q9UNA0 | 17/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29873524 | 1.00 | CYP3A4 (0.68) | CYP3A4ADAMTS5ADAM17MMP2MMP13 | |
| Hydrochloric Acid SCHEMBL23354858 | 0.98 | CYP3A4 (0.67) | CYP3A4ADAMTS5ADAM17MMP2MMP13 | |
| SCHEMBL23367191 | 0.81 | MMP13 (0.52) | CYP3A4ADAMTS5ADAM17MMP13MMP8 | |
| SCHEMBL29873928 | 0.81 | MMP13 (0.52) | CYP3A4ADAMTS5ADAM17MMP13MMP8 | |
| SCHEMBL7907806 | 0.80 | ADAM17 (0.58) | CYP3A4ADAMTS5ADAM17MMP2MMP13 | |
| Hydrochloric Acid SCHEMBL23354880 | 0.80 | MMP13 (0.51) | CYP3A4ADAMTS5ADAM17MMP13MMP8 | |
| Hydrochloric Acid SCHEMBL29873539 | 0.80 | MMP13 (0.51) | CYP3A4ADAMTS5ADAM17MMP13MMP8 | |
| SCHEMBL17884974 | 0.79 | ADAMTS5 (0.65) | CYP3A4ADAMTS5ADAM17MMP2MMP13 | |
| SCHEMBL30609680 | 0.79 | ADAMTS5 (0.65) | CYP3A4ADAMTS5ADAM17MMP2MMP13 | |
| Hydrochloric Acid SCHEMBL23354268 | 0.79 | ADAM17 (0.56) | CYP3A4ADAMTS5ADAM17MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | CYP3A4 3940/4885ADAMTS5 4/4885ADAM17 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.